Miravo Healthcare™ Announces First Quarter 2021 Results
News provided by
Share this article
-
-
-
Miravo to Hold Virtual Annual Meeting May 17th at 9:00 a.m. ET
MISSISSAUGA, ON, May 17, 2021 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2021. For further details on the results, please refer to Miravo s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2021, which are available on the Company s website (www.miravohealthcare.com). All figures are in Canadian dollars, unless otherwise noted.
Deerfield Management and Baylor College of Medicine Announce Blue Square Discoveries to Advance Novel Therapeutic Treatments streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Adaptive Phage Therapeutics Raises $40.75M in Series B Financing
Adaptive Phage Therapeutics (APT), a Gaithersburg, Md.-based clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, closed a $40.75m Series B funding.
The round was led by Deerfield Management Company with participation from existing investor Mayo Clinic and an additional undisclosed institutional investor.
The company intends to use the funds to accelerate clinical development of PhageBank™ phage therapies, as well as for general corporate purposes.
Led by Greg Merril, CEO and Co-Founder, Adaptive Phage Therapeutics is a clinical-stage company advancing therapies to treat multi-drug resistant infections. Originally developed by the biodefense program of U.S. Department of Defense, PhageBank™ technology is a growing collection of hundreds of bacteriophage, collectively providing broad spectrum coverage against six of the highest priority multi-drug resistant bacteri
Two UB drug development and discovery projects have received investments from the Empire Discovery Institute.
Subscribe
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.
The institute will advance both efforts through its Medicines Discovery Award Program, a competitive incubator and accelerator program designed to identify and advance promising early-stage drug discovery into early proofs of concept. Successful projects will exit the program as either a licensing transaction to a strategic pharmaceutical partner or as an Empire Discovery Institute-created startup company.
Two UB drug development and discovery projects have received investments from the Empire Discovery Institute.
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.
The institute will advance both efforts through its Medicines Discovery Award Program, a competitive incubator and accelerator program designed to identify and advance promising early-stage drug discovery into early “proofs of concept.” Successful projects will exit the program as either a licensing transaction to a strategic pharmaceutical partner or as an Empire Discovery Institute-created startup company.